Notably, the limited data available on patients with concurrent NRAS mutations reveal an even more unfavorable prognosis, particularly in patients with metastatic colon tumors, and may be associated with a diminished response to conventional chemotherapy treatments. Here, NRAS is linked to metastatic malignant neoplasm in the colon.